Abstract: The composition disclosed is a pseudo-thermosetting neutralized chitosan composition, neutralized with an hydroxylated base, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C. Said composition contains a homogeneously reacetylated chitosan derived from a chitosan having a deacetylation degree of 80-90%, having a molecular weight of not smaller than 200 kDa and a deacetylation degree of 30-60%, and may further contain a diol. Said composition may be used as a drug delivery system.

Abstract: A fatty acid derivative-polymer conjugate including a conjugate comprising a fatty acid derivative and an alkyl substituted polylactide compound is provided. A pharmaceutical composition comprising the conjugate is also provided.

Abstract: The invention relates to a process for providing esters of hyaluronic acid, hyaluronic acid salts or hyaluronic acid derivatives with hydrophobic organic compounds. The process includes the steps of (i) micronizing the hyaluronic acid, salt or derivative thereof at reduced temperature, (ii) reacting the hydrophobic compound with a micronized hyaluronic acid obtained in (i) in a suitable solvent; and (iii) filtrating or dialyzing reaction mixture obtained in (ii) to obtain the desired ester. Also encompassed by the present invention are the esters obtained by such a method and compositions containing them as well as the use thereof for treating and/or preventing cartilage damage and inflammation.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: A fatty acid derivative-polymer conjugate including a conjugate comprising a fatty acid derivative and an alkyl substituted polylactide compound is provided. A pharmaceutical composition comprising the conjugate is also provided.

Abstract: A tricycle compound-polymer conjugate including a conjugate comprising a tricyclo compound and an alkyl substituted polylactide compound is provided. A pharmaceutical composition comprising the conjugate is also provided.

Abstract: The composition disclosed is a pseudo-thermosetting neutralized chitosan composition, neutralized with a hydroxylated base, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C. Said composition contains a homogeneously reacetylated chitosan derived from a chitosan having a deacetylation degree of 80-90%, having a molecular weight of not smaller than 200 kDa and a deacetylation degree of 30-60%, and may further contain a diol. Said composition may be used as a drug delivery system.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: Described herein are compositions comprising polymers prepared by melt polycondensation of 2-hydroxyalkyl acids. Methods of making and using the compositions are also disclosed.

Abstract: The present invention is directed to stabilized intact antibody formulations, related methods and uses thereof. In particular, the invention relates to a method of stabilizing an intact antibody in a liquid carrier.

Abstract: The present invention is directed to stabilized intact antibody formulations, related methods and uses thereof. In particular, the invention relates to a method of stabilizing an intact antibody in a liquid carrier.

Abstract: The present invention is directed to combination formulations of monoclonal antibodies with anti-inflammatory agents, related methods and uses thereof.

Abstract: The composition disclosed is a pseudo-thermosetting neutralized chitosan composition, neutralized with a hydroxylated base, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C. Said composition contains a homogeneously reacetylated chitosan derived from a chitosan having a deacetylation degree of 80-90%, having a molecular weight of not smaller than 200 kDa and a deacetylation degree of 30-60%, and may further contain a diol. Said composition may be used as a drug delivery system.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: The present invention relates to a device comprising an intraocular lens and a drug delivery system attached thereto, wherein said drug delivery system is or can be loaded with one or more therapeutic agents. Preferably, said drug delivery system comprises a biodegradable matrix material wherein said biodegradable matrix material is preferably selected from the group consisting of: poly(lactic acid), poly(glycolic acid), poly(lactide-co-glycolide), polycaprolactones, polyorthoesters, polyanhydrides, polyesteramides and mixtures thereof. Preferred therapeutic agent(s) is/are selected from anti-inflammatory agents, anti-vasoproliferative agents, immunosuppressive agents, antibiotics, antiviral agents, anti-mitotic agents and combinations thereof. Also provided is a method of treatment and/or prevention of one or more diseases or malfunctions of the eye, comprising implanting one, two, three or more devices of the invention into an eye of a patient.

Abstract: The aqueous thermosetting neutralized chitosan composition, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C., comprises 0.1 to 5.0 w/w %, based on the total composition, of a reacetylated chitosan having a molecular weight of not smaller than 100 kDa and a deacetylation degree of 40 to 70%, neutralized with an hydroxylated base, and 1 to 30 w/w %, based on the total composition, of a complexing agent selected from polyoses and polyols derived from polyoses. Said composition is useful for the preparation of an injectable formulation.

Abstract: The invention provides nanoparticles containing photosensitizers and their use in the field of photodynamic therapy (PDT). The invention also provides methods for the preparation of such nanoparticles as well as for their sterilization.

Abstract: The present invention relates to pharmaceutical compositions for the oral administration of pharmaceutical agents having low water solubility. Those agents are solubilized with a polymer suitable for the formation of nanoparticles, especially from the EUDRAGIT L and S series which release the active agent in specific target regions of the gastrointestinal tract.

Abstract: The composition disclosed is a pseudo-thermosetting neutralized chitosan composition, neutralized with an hydroxylated base, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C. Said composition contains a homogeneously reacetylated chitosan derived from a chitosan having a deacetylation degree of 80-90%, having a molecular weight of not smaller than 200 kDa and a deacetylation degree of 30-60%, and may further contain a diol. Said composition may be used as a drug delivery system.

Abstract: The invention relates to a product for use in agriculture or horticulture comprising a capsule dissolving or disintegrating in the presence of humidity wherein at least a seed and a controlled release system comprising an agrochemical compound is located.